
Sign up to save your podcasts
Or


Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.
Listen in for your chance to get ahead of the markets.
LISTEN ABOVE
See omnystudio.com/listener for privacy information.
By Newstalk ZB5
11 ratings
Andrew Bascand, Managing Director of Harbour Asset Management joins me to discuss new findings of the GLP-1 drug class, which has predominantly been used to treat type 2 diabetes but has captured notable mindshare with healthcare specialists and macro investors.
Listen in for your chance to get ahead of the markets.
LISTEN ABOVE
See omnystudio.com/listener for privacy information.

2 Listeners

8,748 Listeners

11 Listeners

23 Listeners

5 Listeners

1 Listeners

9 Listeners

136 Listeners

0 Listeners

4 Listeners

1 Listeners

23 Listeners

132 Listeners

0 Listeners

288 Listeners

0 Listeners

6 Listeners

0 Listeners

0 Listeners

11 Listeners

15 Listeners

7 Listeners

69 Listeners

6 Listeners

2 Listeners

2 Listeners

0 Listeners

0 Listeners

0 Listeners

2 Listeners

14 Listeners

0 Listeners

0 Listeners